Antihypertensive therapy

Intervention

1 paper2 findings

  • Funder: National Institute on Aging
  • In silico1

Outcomes

2

Cost-effectiveness

upin silico1

1 study
  1. Antihypertensive therapy improves cost-effectiveness in silico (ICER ¥22,489 per QALY in 40s).

    In silicoscreening-detected hypertension20-year horizon

    Cost-effectiveness analysis of early antihypertensive treatment for hypertension detected at health screening

    Hypertension research : official journal of the Japanese Society of Hypertension19 Aug 2026

Quality-adjusted life-years

upin silico1

1 study
  1. Antihypertensive therapy improves quality-adjusted life-years in silico (13.52 vs 12.85 QALYs).

    In silicoscreening-detected hypertension20-year horizon

    Cost-effectiveness analysis of early antihypertensive treatment for hypertension detected at health screening

    Hypertension research : official journal of the Japanese Society of Hypertension19 Aug 2026

Funding

1 grant since 2022

National Institute on AgingUS$909.2k

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 01 in 12 months